Helicobacter pylori and Nonmalignant Diseases

  • Doron BoltinEmail author
  • Yaron Niv


Infection with Helicobacter pylori initially leads to superficial gastritis and usually progresses to chronic active gastritis. Although the vast majority of chronically infected subjects remain asymptomatic, somewhere between 10 % and 15 % develop peptic ulcer disease. Most commonly, H. pylori infection is located in the gastric antrum, where it acts to inhibit somatostatin release and thus stimulate acid secretion, causing duodenal ulceration. Patients with pangastritis are predisposed to developing gastric ulceration. Although population-based studies show that patients with gastroesophageal reflux disease have a lower likelihood of H. pylori infection, there is no robust evidence suggesting that eradication of H. pylori leads to erosive esophagitis. Patients who lack endoscopic evidence of disease such as peptic ulceration (i.e., functional dyspepsia) experience a greater reduction in their dyspeptic symptoms following eradication of H. pylori as compared to placebo. The pathophysiology of H. pylori-mediated dyspepsia in these patients probably involves increased acid, decreased ghrelin, and altered gastric emptying. Eradication of H. pylori in patients with functional dyspepsia has the added benefit of preventing future peptic ulcer disease, especially in Asian populations. H. pylori has been weakly linked to various nonmalignant conditions ranging from halitosis to coronary heart disease. However, evidence in support of actively seeking and treating H. pylori exists only for idiopathic thrombocytopenic purpura and iron deficiency anemia. In epidemiological studies, H. pylori infection has been shown to be inversely associated with Crohn’s disease and asthma.


Helicobacter pylori Peptic ulcer Gastroesophageal reflux Dyspepsia 


  1. Agréus L, Svärdsudd K, Nyrén O, Tibblin G (1995) Irritable bowel syndrome and dyspepsia in the general population: overlap and lack of stability over time. Gastroenterology 109(3):671–680CrossRefPubMedGoogle Scholar
  2. Ashktorab H, Entezari O, Nouraie M, Dowlati E, Frederick W, Woods A, Lee E, Brim H, Smoot DT, Ghadyari F, Kamangar F, Razjouyan H (2012) Helicobacter pylori protection against reflux esophagitis. Dig Dis Sci 57(11):2924–2928. doi: 10.1007/s10620-012-2349-3 CrossRefPubMedPubMedCentralGoogle Scholar
  3. Boltin D, Niv Y (2012) Ghrelin, Helicobacter pylori and body mass: is there an association? Israel Med Assoc J 14(2):130–132Google Scholar
  4. Boltin D, Halpern M, Levi Z, Vilkin A, Morgenstern S, Ho SB, Niv Y (2012) Gastric mucin expression in Helicobacter pylori-related, nonsteroidal anti-inflammatory drug-related and idiopathic ulcers. World J Gastroenterol 18(33):4597–4603. doi: 10.3748/wjg.v18.i33.4597 CrossRefPubMedPubMedCentralGoogle Scholar
  5. Chan FK, Sung JJ, Chung SC, To KF, Yung MY, Leung VK, Lee YT, Chan CS, Li EK, Woo J (1997) Randomised trial of eradication of Helicobacter pylori before non-steroidal anti-inflammatory drug therapy to prevent peptic ulcers. Lancet 350(9083):975–979CrossRefPubMedGoogle Scholar
  6. Chan FKL, Ching JYL, Suen BY, Tse YK, Wu JCY, Sung JJY (2013) Effects of Helicobacter pylori infection on long-term risk of peptic ulcer bleeding in low-dose aspirin users. Gastroenterology 144(3):528–535. doi: 10.1053/j.gastro.2012.12.038 CrossRefPubMedGoogle Scholar
  7. Choe YH, Kim SK, Son BK, Lee DH, Hong YC, Pai SH (1999) Randomized placebo-controlled trial of Helicobacter pylori eradication for iron-deficiency anemia in preadolescent children and adolescents. Helicobacter 4(2):135–139CrossRefPubMedGoogle Scholar
  8. Ciociola AA, McSorley DJ, Turner K, Sykes D, Palmer JB (1999) Helicobacter pylori infection rates in duodenal ulcer patients in the United States may be lower than previously estimated. Am J Gastroenterol 94(7):1834–1840. doi: 10.1111/j.1572-0241.1999.01214.x CrossRefPubMedGoogle Scholar
  9. Des Bruley Varannes S, Fléjou JF, Colin R, Zaïm M, Meunier A, Bidaut-Mazel C (2001) There are some benefits for eradicating Helicobacter pylori in patients with non-ulcer dyspepsia. Aliment Pharmacol Ther 15(8):1177–1185CrossRefGoogle Scholar
  10. Drossman DA (ed) (2006) Rome III the functional gastrointestinal disorders, 3rd edn. Degnon Associates, McLeanGoogle Scholar
  11. DuBois S, Kearney DJ (2005) Iron-deficiency anemia and Helicobacter pylori infection: a review of the evidence. Am J Gastroenterol 100(2):453–459. doi: 10.1111/j.1572-0241.2005.30252.x CrossRefPubMedGoogle Scholar
  12. el-Omar E, Penman I, Dorrian CA, Ardill JE, McColl KE (1993) Eradicating Helicobacter pylori infection lowers gastrin mediated acid secretion by two thirds in patients with duodenal ulcer. Gut 34(8):1060–1065CrossRefPubMedPubMedCentralGoogle Scholar
  13. Fiocca R, Solcia E, Santoro B (1991) Duodenal ulcer relapse after eradication of Helicobacter pylori. Lancet 337(8757):1614CrossRefPubMedGoogle Scholar
  14. Franceschi F, Niccoli G, Ferrante G, Gasbarrini A, Baldi A, Candelli M, Feroce F, Saulnier N, Conte M, Roccarina D, Lanza GA, Gasbarrini G, Gentiloni SN, Crea F (2009) CagA antigen of Helicobacter pylori and coronary instability: insight from a clinico-pathological study and a meta-analysis of 4241 cases. Atherosclerosis 202(2):535–542. doi: 10.1016/j.atherosclerosis. 2008.04.051 CrossRefPubMedGoogle Scholar
  15. Franchini M, Veneri D (2006) Helicobacter pylori -associated immune thrombocytopenia. Platelets 17(2):71–77. doi: 10.1080/09537100500438057 CrossRefPubMedGoogle Scholar
  16. Gillen D, Wirz AA, Ardill JE, McColl KE (1999) Rebound hypersecretion after omeprazole and its relation to on-treatment acid suppression and Helicobacter pylori status. Gastroenterology 116(2):239–247CrossRefPubMedGoogle Scholar
  17. Gisbert JP, Abraira V (2006) Accuracy of Helicobacter pylori diagnostic tests in patients with bleeding peptic ulcer: a systematic review and meta-analysis. Am J Gastroenterol 101(4):848–863. doi: 10.1111/j.1572-0241.2006.00528.x CrossRefPubMedGoogle Scholar
  18. Gisbert JP, Calvet X (2009) Review article: Helicobacter pylori-negative duodenal ulcer disease. Aliment Pharmacol Ther 30(8):791–815. doi: 10.1111/j.1365-2036.2009.04105.x CrossRefPubMedGoogle Scholar
  19. Gisbert JP, Pajares JM (2002) Review article: Helicobacter pylori infection and gastric outlet obstruction – prevalence of the infection and role of antimicrobial treatment. Aliment Pharmacol Ther 16(7):1203–1208CrossRefPubMedGoogle Scholar
  20. Gisbert JP, Blanco M, Mateos JM, Fernández-Salazar L, Fernández-Bermejo M, Cantero J, Pajares JM (1999) H. pylori-negative duodenal ulcer prevalence and causes in 774 patients. Dig Dis Sci 44(11):2295–2302CrossRefPubMedGoogle Scholar
  21. Gisbert JP, Calvet X, Cosme A, Almela P, Feu F, Bory F, Santolaria S, Aznárez R, Castro M, Fernández N, García-Grávalos R, Benages A, Cañete N, Montoro M, Borda F, Pérez-Aisa A, Piqué JM (2012) Long-term follow-up of 1,000 patients cured of Helicobacter pylori infection following an episode of peptic ulcer bleeding. Am J Gastroenterol 107(8):1197–1204. doi: 10.1038/ajg.2012.132 CrossRefPubMedGoogle Scholar
  22. Goodman KJ, Joyce SL, Ismond KP (2006) Extragastric diseases associated with Helicobacter pylori infection. Curr Gastroenterol Rep 8(6):458–464CrossRefPubMedGoogle Scholar
  23. Gwee K, Teng L, Wong RM, Ho K, Sutedja D, Yeoh K (2009) The response of Asian patients with functional dyspepsia to eradication of Helicobacter pylori infection. Eur J Gastroenterol Hepatol 21(4):417–424. doi: 10.1097/MEG.0b013e328317b89e CrossRefPubMedGoogle Scholar
  24. Hall W, Buckley M, Crotty P, O’Morain CA (2003) Gastric mucosal mast cells are increased in Helicobacter pylori-negative functional dyspepsia. Clin Gastroenterol Hepatol 1(5):363–369CrossRefPubMedGoogle Scholar
  25. Holtmann G, Cain C, Malfertheiner P (1999) Gastric Helicobacter pylori infection accelerates healing of reflux esophagitis during treatment with the proton pump inhibitor pantoprazole. Gastroenterology 117(1):11–16CrossRefPubMedGoogle Scholar
  26. Hsu PI, Lai KH, Tseng HH, Lo GH, Lo CC, Lin CK, Cheng JS, Chan HH, Ku MK, Peng NJ, Chien EJ, Chen W, Hsu PN (2001) Eradication of Helicobacter pylori prevents ulcer development in patients with ulcer-like functional dyspepsia. Aliment Pharmacol Ther 15(2):195–201CrossRefPubMedGoogle Scholar
  27. Huang JQ, Sridhar S, Hunt RH (2002) Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis. Lancet 359(9300):14–22. doi: 10.1016/S0140-6736(02)07273-2 CrossRefPubMedGoogle Scholar
  28. Jang HJ, Choi MH, Shin WG, Kim KH, Chung YW, Kim KO, Park CH, Baek IH, Baik KH, Kae SH, Kim HY (2008) Has peptic ulcer disease changed during the past ten years in Korea? A prospective multi-center study. Dig Dis Sci 53(6):1527–1531. doi: 10.1007/s10620-007-0028-6 CrossRefPubMedGoogle Scholar
  29. Jyotheeswaran S, Shah AN, Jin HO, Potter GD, Ona FV, Chey WY (1998) Prevalence of Helicobacter pylori in peptic ulcer patients in greater Rochester, NY: is empirical triple therapy justified? Am J Gastroenterol 93(4):574–578. doi: 10.1111/j.1572-0241.1998.167_b.x CrossRefPubMedGoogle Scholar
  30. Katsinelos P, Tziomalos K, Chatzimavroudis G, Vasiliadis T, Katsinelos T, Pilpilidis I, Triantafillidis I, Paroutoglou G, Papaziogas B (2007) Eradication therapy in Helicobacter pylori-positive patients with halitosis: long-term outcome. Med Princ Pract 16(2):119–123. doi: 10.1159/000098364 CrossRefPubMedGoogle Scholar
  31. Kuipers EJ, Lundell L, Klinkenberg-Knol EC, Havu N, Festen HP, Liedman B, Lamers CB, Jansen JB, Dalenback J, Snel P, Nelis GF, Meuwissen SG (1996) Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication. N Engl J Med 334(16):1018–1022. doi: 10.1056/NEJM199604183341603 CrossRefPubMedGoogle Scholar
  32. Lan L, Yu J, Chen Y, Zhong Y, Zhang H, Jia C, Yuan Y, Liu B (2011) Symptom-based tendencies of Helicobacter pylori eradication in patients with functional dyspepsia. World J Gastroenterol 17(27):3242–3247. doi: 10.3748/wjg.v17.i27.3242 PubMedPubMedCentralGoogle Scholar
  33. Lanza FL, Chan FKL, Quigley EMM (2009) Guidelines for prevention of NSAID-related ulcer complications. Am J Gastroenterol 104(3):728–738. doi: 10.1038/ajg.2009.115 CrossRefPubMedGoogle Scholar
  34. Lee H, Kho H, Chung J, Chung S, Kim Y (2006) Volatile sulfur compounds produced by Helicobacter pylori. J Clin Gastroenterol 40(5):421–426CrossRefPubMedGoogle Scholar
  35. Luther J, Dave M, Higgins PDR, Kao JY (2010) Association between Helicobacter pylori infection and inflammatory bowel disease: a meta-analysis and systematic review of the literature. Inflamm Bowel Dis 16(6):1077–1084. doi: 10.1002/ibd.21116 CrossRefPubMedGoogle Scholar
  36. Luther J, Owyang SY, Takeuchi T, Cole TS, Zhang M, Liu M, Erb-Downward J, Rubenstein JH, Chen C, Pierzchala AV, Paul JA, Kao JY (2011) Helicobacter pylori DNA decreases pro-inflammatory cytokine production by dendritic cells and attenuates dextran sodium sulphate-induced colitis. Gut 60(11):1479–1486. doi: 10.1136/gut.2010.220087 CrossRefPubMedPubMedCentralGoogle Scholar
  37. Malfertheiner P, Megraud F, O’Morain CA, Atherton J, Axon ATR, Bazzoli F, Gensini GF, Gisbert JP, Graham DY, Rokkas T, El-Omar EM, Kuipers EJ (2012) Management of Helicobacter pylori infection – the Maastricht IV/Florence consensus report. Gut 61(5):646–664. doi: 10.1136/gutjnl-2012-302084 CrossRefPubMedGoogle Scholar
  38. Marshall BJ, Armstrong JA, McGechie DB, Glancy RJ (1985) Attempt to fulfil Koch’s postulates for pyloric Campylobacter. Med J Aust 142(8):436–439PubMedGoogle Scholar
  39. Marshall BJ, Goodwin CS, Warren JR, Murray R, Blincow ED, Blackbourn SJ, Phillips M, Waters TE, Sanderson CR (1988) Prospective double-blind trial of duodenal ulcer relapse after eradication of Campylobacter pylori. Lancet 2(8626–8627):1437–1442CrossRefPubMedGoogle Scholar
  40. Mazzoleni LE, Sander GB, Francesconi CFM, Mazzoleni F, Uchoa DM, de Bona LR, Milbradt TC, von Reisswitz PS, Berwanger O, Bressel M, Edelweiss MI, Marini SS, Molina CG, Folador L, Lunkes RP, Heck R, Birkhan OA, Spindler BM, Katz N, Colombo BS, Guerrieri PP, Renck LB, Grando E, Hocevar de Moura B, Dahmer FD, Rauber J, Prolla JC (2011) Helicobacter pylori eradication in functional dyspepsia: HEROES trial. Arch Intern Med 171(21):1929–1936. doi: 10.1001/archinternmed.2011.533 CrossRefPubMedGoogle Scholar
  41. Moayyedi P, Soo S, Deeks J, Forman D, Mason J, Innes M, Delaney B (2000a) Systematic review and economic evaluation of Helicobacter pylori eradication treatment for non-ulcer dyspepsia. Dyspepsia Review Group. BMJ 321(7262):659–664CrossRefPubMedPubMedCentralGoogle Scholar
  42. Moayyedi P, Wason C, Peacock R, Walan A, Bardhan K, Axon AT, Dixon MF (2000b) Changing patterns of Helicobacter pylori gastritis in long-standing acid suppression. Helicobacter 5(4):206–214CrossRefPubMedGoogle Scholar
  43. Moayyedi P, Soo S, Deeks JJ, Delaney B, Harris A, Innes M, Oakes R, Wilson S, Roalfe A, Bennett C, Forman D (2011) WITHDRAWN: eradication of Helicobacter pylori for non-ulcer dyspepsia. Cochrane Database Syst Rev 2:CD002096. doi: 10.1002/14651858.CD002096.pub5 PubMedGoogle Scholar
  44. Oertli M, Müller A (2012) Helicobacter pylori targets dendritic cells to induce immune tolerance, promote persistence and confer protection against allergic asthma. Gut Microbes 3(6):566–571. doi: 10.4161/gmic.21750 CrossRefPubMedPubMedCentralGoogle Scholar
  45. Raghunath A (2003) Prevalence of Helicobacter pylori in patients with gastro-oesophageal reflux disease: systematic review. BMJ 326(7392):737. doi: 10.1136/bmj.326.7392.737 CrossRefPubMedPubMedCentralGoogle Scholar
  46. Rokkas T, Pistiolas D, Sechopoulos P, Robotis I, Margantinis G (2007) Relationship between Helicobacter pylori infection and esophageal neoplasia: a meta-analysis. Clin Gastroenterol Hepatol 5(12):1413–1417.e1-2. doi: 10.1016/j.cgh.2007.08.010 CrossRefPubMedGoogle Scholar
  47. Saad AM, Choudhary A, Bechtold ML (2012) Effect of Helicobacter pylori treatment on gastroesophageal reflux disease (GERD): meta-analysis of randomized controlled trials. Scand J Gastroenterol 47(2):129–135. doi: 10.3109/00365521.2011.648955 CrossRefPubMedGoogle Scholar
  48. Saito Y, Suzuki H, Tsugawa H, Suzuki S, Matsuzaki J, Hirata K, Hibi T (2011) Dysfunctional gastric emptying with down-regulation of muscle-specific microRNAs in Helicobacter pylori-infected mice. Gastroenterology 140(1):189–198. doi: 10.1053/j.gastro.2010.08.044 CrossRefPubMedGoogle Scholar
  49. Sánchez-Delgado J, Gené E, Suárez D, García-Iglesias P, Brullet E, Gallach M, Feu F, Gisbert JP, Calvet X (2011) Has H. pylori prevalence in bleeding peptic ulcer been underestimated? A meta-regression. Am J Gastroenterol 106(3):398–405. doi: 10.1038/ajg.2011.2 CrossRefPubMedGoogle Scholar
  50. Schenk BE, Kuipers EJ, Klinkenberg-Knol EC, Eskes SA, Meuwissen SG (1999) Helicobacter pylori and the efficacy of omeprazole therapy for gastroesophageal reflux disease. Am J Gastroenterol 94(4):884–887. doi: 10.1111/j.1572-0241.1999.982_e.x CrossRefPubMedGoogle Scholar
  51. Schubert ML, Peura DA (2008) Control of gastric acid secretion in health and disease. Gastroenterology 134(7):1842–1860. doi: 10.1053/j.gastro.2008.05.021 CrossRefPubMedGoogle Scholar
  52. Stack WA, Atherton JC, Hawkey GM, Logan RFA, Hawkey CJ (2002) Interactions between Helicobacter pylori and other risk factors for peptic ulcer bleeding. Aliment Pharmacol Ther 16(3):497–506CrossRefPubMedGoogle Scholar
  53. Sugano K (2011) Should we still subcategorize helicobacter pylori-associated dyspepsia as functional disease? J Neurogastroenterol Motil 17(4):366–371. doi: 10.5056/jnm.2011.17.4.366 CrossRefPubMedPubMedCentralGoogle Scholar
  54. Sung JJY, Kuipers EJ, El-Serag HB (2009) Systematic review: the global incidence and prevalence of peptic ulcer disease. Aliment Pharmacol Ther 29(9):938–946. doi: 10.1111/j.1365-2036.2009.03960.x CrossRefPubMedGoogle Scholar
  55. Talley NJ, Janssens J, Lauritsen K, Rácz I, Bolling-Sternevald E (1999) Eradication of Helicobacter pylori in functional dyspepsia: randomised double blind placebo controlled trial with 12 months’ follow up. The Optimal Regimen Cures Helicobacter Induced Dyspepsia (ORCHID) Study Group. BMJ 318(7187):833–837CrossRefPubMedPubMedCentralGoogle Scholar
  56. Tas A, Köklü S, Yüksel I, Başar O, Akbal E, Cimbek A (2011) No significant association between halitosis and upper gastrointestinal endoscopic findings: a prospective study. Chin Med J 124(22):3707–3710PubMedGoogle Scholar
  57. Tomtitchong P, Siribumrungwong B, Vilaichone R, Kasetsuwan P, Matsukura N, Chaiyakunapruk N (2012) Systematic review and meta-analysis: Helicobacter pylori eradication therapy after simple closure of perforated duodenal ulcer. Helicobacter 17(2):148–152. doi: 10.1111/j.1523-5378.2011.00928.x CrossRefPubMedGoogle Scholar
  58. Vaira D, Menegatti M, Miglioli M (1997) What is the role of Helicobacter pylori in complicated ulcer disease? Gastroenterology 113(6 Suppl):S78–S84CrossRefPubMedGoogle Scholar
  59. Vergara M, Catalán M, Gisbert JP, Calvet X (2005) Meta-analysis: role of Helicobacter pylori eradication in the prevention of peptic ulcer in NSAID users. Aliment Pharmacol Ther 21(12):1411–1418. doi: 10.1111/j.1365-2036.2005.02444.x CrossRefPubMedGoogle Scholar
  60. Wang Q, Yu C, Sun Y (2013) The association between asthma and Helicobacter pylori: a meta-analysis. Helicobacter 18(1):41–53. doi: 10.1111/hel.12012 CrossRefPubMedGoogle Scholar
  61. Zhou X, Wu J, Zhang G (2013) Association between Helicobacter pylori and asthma: a meta-analysis. Eur J Gastroenterol Hepatol 25(4):460–468. doi: 10.1097/MEG.0b013e32835c280a PubMedGoogle Scholar

Copyright information

© Springer Japan 2016

Authors and Affiliations

  1. 1.Department of GastroenterologyRabin Medical Center, Beilinson CampusPetah TikvaIsrael

Personalised recommendations